Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world
Abstract Background Mesenchymal to epithelial transition factor (MET) dysregulation in non-small-cell-lung-cancer (NSCLC) is understudied, with scant data on treatment outcomes. Methods We retrospectively examined 160 NSCLC patients: 125 with primary MET mutations (further classified into MET exon 1...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-024-03437-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586041816514560 |
|---|---|
| author | Mengmeng Li Jiuyan Huang Ruyue Xing Xinyang Du Chunhua Wei Huijuan Wang |
| author_facet | Mengmeng Li Jiuyan Huang Ruyue Xing Xinyang Du Chunhua Wei Huijuan Wang |
| author_sort | Mengmeng Li |
| collection | DOAJ |
| description | Abstract Background Mesenchymal to epithelial transition factor (MET) dysregulation in non-small-cell-lung-cancer (NSCLC) is understudied, with scant data on treatment outcomes. Methods We retrospectively examined 160 NSCLC patients: 125 with primary MET mutations (further classified into MET exon 14 (METex14) skipping mutations and primary MET amplifications) and 35 with secondary MET amplifications. Patients underwent varied treatments: Chemotherapy, Immune monotherapy, Crizotinib, or Savolitinib. Secondary MET amplification patients were grouped by treatment: Group A (Class Ib MET-TKI with third-generation EGFR-TKI), Group B (Crizotinib with first-generation EGFR-TKI), and Group C (Crizotinib alone). One hundred and thirty patients have completed the whole treatment process. Their data were included in the study's survival analysis (included 95 patients with primary MET mutations and 35 patients with secondary MET amplifications). Results Among METex14 skipping mutations patients (n = 57), median progression free survival (PFS) was: Chemotherapy 7.64 m, Crizotinib 8.5 m, Savolitinib 9.3 m, and Immunotherapy 3.87 m. Targeted therapies and chemotherapy significantly outperformed Immunotherapy. Sub-group analysis indicated splice donor region mutations benefited more than those at the polypyrimidine tract (9.23 m vs. 4.03 m, P = 0.038). For primary MET amplifications (n = 38), PFS was: Chemotherapy 2.84 m, Crizotinib 3.80 m, Savolitinib 5.23 m, and Immunotherapy 3.30 m. Patients with copy number (CN) > 5 had longer PFS than CN ≤ 5 (5.17 m vs. 3.44 m, P = 0.039). In secondary MET amplifications (n = 35), Group A and B had similar PFS (6.77 m and 6.57 m) versus Group C (3.13 m). Dual-target therapy PFS showed no difference between CN ≤ 5 and CN > 5 (8.63 m vs. 6.27 m, P = 0.29). Conclusion NSCLC patients with METex14 skipping mutations benefit more from targeted therapies, especially those with splice donor mutations. MET amplification patients benefit universally from targeted therapies; primary MET amplifications show higher benefits with increased copy numbers. For secondary MET amplifications post-EGFR-TKI resistance, dual-target therapy surpasses Crizotinib monotherapy, independent of MET copy number. |
| format | Article |
| id | doaj-art-2bb677e86c064b55869e16fa485e46a7 |
| institution | Kabale University |
| issn | 1471-2466 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj-art-2bb677e86c064b55869e16fa485e46a72025-01-26T12:13:08ZengBMCBMC Pulmonary Medicine1471-24662025-01-0125111110.1186/s12890-024-03437-4Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real worldMengmeng Li0Jiuyan Huang1Ruyue Xing2Xinyang Du3Chunhua Wei4Huijuan Wang5Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Medical Oncology, Nanyang Central HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalAbstract Background Mesenchymal to epithelial transition factor (MET) dysregulation in non-small-cell-lung-cancer (NSCLC) is understudied, with scant data on treatment outcomes. Methods We retrospectively examined 160 NSCLC patients: 125 with primary MET mutations (further classified into MET exon 14 (METex14) skipping mutations and primary MET amplifications) and 35 with secondary MET amplifications. Patients underwent varied treatments: Chemotherapy, Immune monotherapy, Crizotinib, or Savolitinib. Secondary MET amplification patients were grouped by treatment: Group A (Class Ib MET-TKI with third-generation EGFR-TKI), Group B (Crizotinib with first-generation EGFR-TKI), and Group C (Crizotinib alone). One hundred and thirty patients have completed the whole treatment process. Their data were included in the study's survival analysis (included 95 patients with primary MET mutations and 35 patients with secondary MET amplifications). Results Among METex14 skipping mutations patients (n = 57), median progression free survival (PFS) was: Chemotherapy 7.64 m, Crizotinib 8.5 m, Savolitinib 9.3 m, and Immunotherapy 3.87 m. Targeted therapies and chemotherapy significantly outperformed Immunotherapy. Sub-group analysis indicated splice donor region mutations benefited more than those at the polypyrimidine tract (9.23 m vs. 4.03 m, P = 0.038). For primary MET amplifications (n = 38), PFS was: Chemotherapy 2.84 m, Crizotinib 3.80 m, Savolitinib 5.23 m, and Immunotherapy 3.30 m. Patients with copy number (CN) > 5 had longer PFS than CN ≤ 5 (5.17 m vs. 3.44 m, P = 0.039). In secondary MET amplifications (n = 35), Group A and B had similar PFS (6.77 m and 6.57 m) versus Group C (3.13 m). Dual-target therapy PFS showed no difference between CN ≤ 5 and CN > 5 (8.63 m vs. 6.27 m, P = 0.29). Conclusion NSCLC patients with METex14 skipping mutations benefit more from targeted therapies, especially those with splice donor mutations. MET amplification patients benefit universally from targeted therapies; primary MET amplifications show higher benefits with increased copy numbers. For secondary MET amplifications post-EGFR-TKI resistance, dual-target therapy surpasses Crizotinib monotherapy, independent of MET copy number.https://doi.org/10.1186/s12890-024-03437-4Mesenchymal-epithelial transition factorNon-small cell lung cancerCrizotinibSavolitinib |
| spellingShingle | Mengmeng Li Jiuyan Huang Ruyue Xing Xinyang Du Chunhua Wei Huijuan Wang Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world BMC Pulmonary Medicine Mesenchymal-epithelial transition factor Non-small cell lung cancer Crizotinib Savolitinib |
| title | Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world |
| title_full | Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world |
| title_fullStr | Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world |
| title_full_unstemmed | Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world |
| title_short | Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world |
| title_sort | exploring practical experience with different treatments in nsclc patients with met deregulated a retrospective analysis from the real world |
| topic | Mesenchymal-epithelial transition factor Non-small cell lung cancer Crizotinib Savolitinib |
| url | https://doi.org/10.1186/s12890-024-03437-4 |
| work_keys_str_mv | AT mengmengli exploringpracticalexperiencewithdifferenttreatmentsinnsclcpatientswithmetderegulatedaretrospectiveanalysisfromtherealworld AT jiuyanhuang exploringpracticalexperiencewithdifferenttreatmentsinnsclcpatientswithmetderegulatedaretrospectiveanalysisfromtherealworld AT ruyuexing exploringpracticalexperiencewithdifferenttreatmentsinnsclcpatientswithmetderegulatedaretrospectiveanalysisfromtherealworld AT xinyangdu exploringpracticalexperiencewithdifferenttreatmentsinnsclcpatientswithmetderegulatedaretrospectiveanalysisfromtherealworld AT chunhuawei exploringpracticalexperiencewithdifferenttreatmentsinnsclcpatientswithmetderegulatedaretrospectiveanalysisfromtherealworld AT huijuanwang exploringpracticalexperiencewithdifferenttreatmentsinnsclcpatientswithmetderegulatedaretrospectiveanalysisfromtherealworld |